Core Alternative Capital Eli Lilly & CO Transaction History

Core Alternative Capital

$484 Million
Q2 2024

A detailed history of Core Alternative Capital transactions in Eli Lilly & CO stock. As of the latest transaction made, Core Alternative Capital holds 16,686 shares of LLY stock, worth $13 Million. This represents 3.12% of its overall portfolio holdings.

Number of Shares

16,686

Previous 18,441 9.52%

Holding current value

$13 Million

Previous $14.3 Million 5.3%

% of portfolio

3.12%

Previous 2.58%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 16, 2024	SELL	$724.87 - $909.04 $1.27 Million - $1.6 Million	-1,755 Reduced 9.52%	16,686 $15.1 Million
Q1 2024 May 15, 2024	SELL	$592.2 - $792.28 $3.95 Million - $5.28 Million	-6,670 Reduced 26.56%	18,441 $14.3 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $6.02 Million - $7.1 Million	-11,468 Reduced 31.35%	25,111 $14.6 Million
Q3 2023 Oct 19, 2023	SELL	$434.7 - $599.3 $549,895 - $758,114	-1,265 Reduced 3.34%	36,579 $19.6 Million
Q2 2023 Jul 27, 2023	SELL	$350.74 - $468.98 $5 Million - $6.68 Million	-14,249 Reduced 27.35%	37,844 $17.7 Million
Q1 2023 Apr 18, 2023	SELL	$310.63 - $364.82 $2.57 Million - $3.02 Million	-8,287 Reduced 13.72%	52,093 $17.9 Million
Q4 2022 Jan 31, 2023	BUY	$321.55 - $374.67 $1.28 Million - $1.49 Million	3,972 Added 7.04%	60,380 $22.1 Million
Q3 2022 Oct 18, 2022	BUY	$296.48 - $337.87 $4.94 Million - $5.63 Million	16,674 Added 41.96%	56,408 $18.2 Million
Q2 2022 Aug 01, 2022	BUY	$278.73 - $327.27 $1.8 Million - $2.11 Million	6,452 Added 19.39%	39,734 $12.9 Million
Q1 2022 May 10, 2022	SELL	$234.69 - $291.66 $1.67 Million - $2.08 Million	-7,128 Reduced 17.64%	33,282 $9.53 Million
Q4 2021 Feb 11, 2022	SELL	$224.85 - $279.04 $232,270 - $288,248	-1,033 Reduced 2.49%	40,410 $9.98 Million
Q3 2021 Nov 05, 2021	SELL	$221.6 - $272.71 $223,151 - $274,618	-1,007 Reduced 2.37%	41,443 $9.58 Million
Q2 2021 Aug 05, 2021	BUY	$180.55 - $233.54 $996,274 - $1.29 Million	5,518 Added 14.94%	42,450 $9.74 Million
Q1 2021 May 13, 2021	BUY	$164.32 - $212.72 $150,681 - $195,064	917 Added 2.55%	36,932 $6.9 Million
Q4 2020 Feb 12, 2021	BUY	$130.46 - $172.63 $253,222 - $335,074	1,941 Added 5.7%	36,015 $6.08 Million
Q3 2020 Oct 09, 2020	SELL	$146.22 - $169.13 $466,149 - $539,186	-3,188 Reduced 8.56%	34,074 $5.04 Million
Q2 2020 Jul 13, 2020	SELL	$136.42 - $164.18 $514,439 - $619,122	-3,771 Reduced 9.19%	37,262 $6.12 Million
Q1 2020 Jun 09, 2020	BUY	$119.05 - $147.35 $2.88 Million - $3.56 Million	24,181 Added 143.49%	41,033 $5.69 Million
Q4 2019 Jun 05, 2020	BUY	$106.92 - $132.43 $1.8 Million - $2.23 Million	16,852 New	16,852 $2.21 Million

Others Institutions Holding LLY

# of Institutions

3,916

Shares Held

765M

Call Options Held

6.34M

Put Options Held

7.96M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $738B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.

Account

Core Alternative Capital Eli Lilly & CO Transaction History